Nonagen Bioscience Granted FDA Breakthrough Device Designation

LOS ANGELES: LOS ANGELES, Sept. 28, 2021 /PRNewswire/ -- Nonagen Bioscience Corp, pioneers in the development of liquid biopsy tests for the detection of human cancers, today announced Oncuria™, their non-invasive bladder cancer test capable of predicting response to therapy, has been granted U.S. Food and Drug Administration (FDA) Breakthrough...

Click to view original post